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Imatinib is a chemotherapeutic drug used for the treatment of chronic myeloid leukemia (CML). Recent
data showed imatinib-induced cell death in various types of cancers. Autophagy is the physiological
process in which cellular components are broken down by the lysosomal activation. In this study, we aimed
to examine the effects of imatinib on autophagy in addition to apoptosis in CML cells. Results suggested
that imatinib induces autophagy in CML cells through inducing over-expression of BECLIN-1 and ATG5
genes with the statistical significance. Our results demonstrated that autophagy might be involved in
imatinib-induced cell death.
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Introduction
Chronic myeloid leukemia (CML) is a blood cancer
caused by the replacement of healthy bone marrow
cells with malignantly transformed leukemic cells and
increased numbers of immature white blood cells in
the bloodstream and blood forming tissues. The
reciprocal translocation between the ninth and the
twenty-second chromosomes bringing the breakpoint
cluster region (BCR) gene and V-abl Abelson murine
leukemia viral oncogene homolog (ABL) gene
together is the main driving force of the malignant
transformation. Resultant structure of this transloca-
tion is called Philadelphia chromosome. The BCR/
ABL protein resulting from this translocation exerts
constitutive tyrosine kinase activity which is impor-
tant for signaling the cell to proliferate. Besides
inducing cell proliferation, BCR/ABL is involved in
differentiation, prevention of apoptosis, cell adhesion
and migration.1–3 Therefore, this fusion protein is an
important target for the treatment of CML.
Imatinib (STI-571) is a chemotherapeutic agent
that specifically binds to the adenosine triphosphate
binding pocket of the BCR/ABL fusion protein. This
binding inhibits the subsequent phosphorylation
events of the target proteins and suppresses cell
proliferation. Imatinib is highly selective for the
transformed cells and it does not have cytotoxic
effect up to the concentration of 10 mM on BCR/
ABL-negative cells.4 Because of the selective nature
of the drug, it is commonly used for the treatment of
Philadelphia chromosome-positive CML. In some of
the patients, there are some mechanisms developed to
gain resistance to imatinib. Resistance to chemother-
apeutic agents such as imatinib is under active
investigation and, with the increasing knowledge in
this subject, we are able to delineate mechanisms
underlying this phenomenon.5,6 We have also shown
in our previous studies that the bioactive sphingoli-
pids are also important in the development of
imatinib resistance in CML.7
Recycling the cellular components is as important as
producing the new ones to maintain the homeostasis.
Autophagy is the regulated pathway for cells to recycle
their components. It is observed in basal levels in
almost all types of cells in order to maintain the
turnover of the organelles and long-lived proteins.8
Components of cells are degraded through activation
of the lysosomal machinery upon induction of
autophagy. Under starvation conditions, cells degrade
some of their internal components via autophagy to
derive monomers which will subsequently be used for
the production of energy. There are three known types
of autophagy: macroautophagy, microautophagy, and
chaperone-mediated autophagy. The first type is
characterized by the encompassment of cellular
components such as organelles and cytosolic protein
aggregates by a double-membrane structure called
autophagosome. This event can be initiated through
the activation of serine/threonine kinase target of
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rapamycin (TOR) upon nutrient starvation.9 ATG
family of genes having more than 15 members is
important in the initiation, expansion, and completion
of the autophagosome.10 Especially ATG5 (or
APG5L) is required for the vesicle expansion and
completion.11,12 ATG6 (or BECLIN-1) is responsible
for vesicle nucleation by forming the phosphatidyli-
nositol 3-kinase complex along with Vps15 and Vps34
proteins.13,14 LC3 (or MAP1ALC3) is another key
player required for the autophagosome expansion.15
Completion of autophagosome harboring the cargo to
be degraded is followed by the fusion with the
lysosome. The fusion event requires some proteins
other than ATG family members such as Vam3,
Vam7, and Ypt7.16 After fusion of autophagosome
with lysosome, hydrolases degrade its constituents and
resultant monomers can be further utilized by the cell.
Unlike macroautophagy, in microautophagy, the
cytoplasmic components are not surrounded by
membrane that is to be fused with lysosome unlike
the macroautophagy. Instead, lysosome engulfs tar-
gets to be degraded by invagination of the lysosomal
membrane. This type of autophagy can also be
initiated by mTOR signaling when nutrient in the
medium is deprived and it is useful for decreasing the
volume of the lysosome inside the cell since invagi-
nated portion of the vacuolar membrane is degraded.17
The last known mechanism of the autophagy,
chaperone-mediated autophagy, involves degradation
of individual proteins. Autophagy plays roles in
various physiological and pathophysiological pro-
cesses in organisms. Activation of autophagy pathway
may have positive or negative effects on the cell
integrity. Tumor suppression and type-II programmed
death of cancer cells, defense against bacterial or viral
infection, and prevention of neurodegeneration via
degrading toxic protein aggregates can be given as
examples of positive outcomes of autophagy. But in
some other cases, autophagy might also contribute to
tumor cell survival under nutrient-deprived conditions
or by protection against cancer treatments.18–20
Deregulation of autophagy may cause mortality of
the cells due to excessive degradation of self-materials
in muscular diseases or such a scenario may also
provide the pathogens with a suitable environment for
their growth by supplying nutrients. Controversial as
it sounds, autophagy might also cause the death of
neuronal cells that harbor protein aggregates and thus
contribute to neurodegenerative diseases. The role of
autophagy in health and disease is currently under the
intensive scope of scientific research as it was reviewed
by numerous authors.8,21,22
In the present study, we aimed to demonstrate the
effects of imatinib in terms of autophagic induction
on human CML cells. By this approach, we will
shed light upon the link between autophagy and
chemotherapy which might have important outcomes
in the clinic.
Materials and Methods
Cell culture
Human K562 CML cells were obtained from the
German Collection of Microorganisms and Cell
Cultures and maintained in RPMI1640 (Roswell
Park Memorial Institute) medium containing 10%
fetal bovine serum and 1% penicillin-streptomycin in
5% CO2 in a CO2 incubator at 37uC.
Gene expression analysis
Changes in the expression levels of autophagy related
genes after the treatment with different concentra-
tions of imatinib were quantified by SYBR Green-
based quantitative polymerase chain reaction (qPCR)
technique. Cells were incubated in the presence of
increasing concentrations of imatinib, and total RNA
was isolated using NucleoSpin Total RNA Isolation
kit (Macherey-Nagel, Duren, Germany) according to
manufacturer protocols. Isolated RNAs were con-
verted to cDNA using First Strand cDNA Synthesis
kit (Fermentas, Glen Burnie, MD, USA). Then,
reverse transcriptase-PCR (RT-PCR) was performed
with beta-actin (F; CAGAGCAAGAGAGGCAT-
CCT, R; TTGAAGGTCTCAAACATGAT), ATG5
(F; TGTCATTTTGCAATCCCATC, R; TTTGGC-
TTTGGTTGAAATAAG), and BECLIN-1(F; CA-
AGATCCTGGACCGTGTCA, R; TGGCACTTT-
CTGTGGACATCA) primers. Bands observed in the
agarose gel electrophoresis were quantified by the
Quantity One 1D Gel Imaging software (BioRad,
Hercules, CA, USA). The intensities of the bands
were normalized to beta-actin controls. Differences
found by those calculations were correlated to the
changes in the expression levels. In order to confirm
densitometric analysis of PCR bands, qPCR was
performed with the same primers by using
LightCyclerH FastStart DNA Master SYBR Green
I kit (Roche, Basel, Switzerland). Finally, the data
were analyzed with REST 2008 software (Corbett
Research, Sydney, Australia).
Immunoblotting
In order to reveal the changes in protein levels, K562
cells were treated with increasing concentrations of
imatinib for 72 hours. Following this treatment, cells
were collected and lysed with lysis buffer [10 ml
dithiothreitol (10 mM), 10 ml NP-40, 50 ml NaCl
(3M), 50 ml ethylenediaminetetraacetic acid (20 mM),
and protease inhibitors aprotinin, leupeptin, pepstatin,
phenylmethylsulfonyl fluoride, and 50 ml Tris-buffered
saline (1M, pH 7.5)] for 15 minutes on ice. Super-
natant was harvested after centrifugation and protein
concentration was measured via bicinchoninic acid
protein assay kit. Equal amounts of lysates including
the proteins were prepared and run on 12.5% sodium
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dodecyl sulfate polyacrylamide gel electrophoresis.
Finally, immunoblotting was performed by using
biotin labeled anti-actin, anti-atg6 and anti-beclin-1
antibodies (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA, USA).
Results
Reverse transcriptase-PCR
We previously determined the cytotoxic effects of
imatinib on K562 cells.23 In this study, IC50 value
(the concentration of any chemical that inhibits cell
proliferation 50% as compared to untreated control
counterparts) of imatinib was found as 280 nM in
K562 cells. To prevent a devastating effect of
imatinib on K562 cells, we picked lower concentra-
tions of imatinib for PCR experiments. Products of
the PCR amplification appeared on agarose gel as
seen in Fig. 1. Reverse transcriptase-PCR (RT-PCR)
results demonstrated that there were significant
increases in expression levels of Beclin-1 and ATG5
as compared to untreated control counterparts and
normalized to beta-actin in response to 0.1, 1, and
10 nM imatinib. Changes in expression levels of
Beclin-1 and ATG5 genes were quantified by assessing
the band intensities. Expression levels of Beclin-1
were increased 1.25-, 1.67-, and 1.84-fold in response
to 0.1, 1, and 10 nM imatinib concentrations in K562
cells (Fig. 2A). As shown in Fig. 2B, there were 1.55-,
1.50-, and 1.71-fold increases in expression levels of
ATG5 in K562 cells exposed to 0.1, 1, and 10 nM
imatinib, respectively. The results revealed that there
were dose dependent increases in expression levels of
ATG5 and Beclin-1 genes in K562 cells.
qPCR analysis
In order to validate densitometric analysis of RT-PCR
products, qPCR was performed to determine the
relative expression levels of Beclin-1. The results
demonstrated that the same concentrations of imatinib
increased expression levels of Beclin-1 1.29-, 1.36-, and
2.25-fold as compared to untreated controls and
normalized to beta-actin levels (Fig. 3).
Immunoblotting
Protein levels of BECLIN-1 gene under the different
concentrations of imatinib were assessed via immu-
noblotting. Immunoblotting analyses demonstrated
dose dependent increases in protein levels of
BECLIN-1 gene as compared to untreated controls
(Fig. 4A). Densitometric analysis was performed to
quantify the protein levels and the results showed
that there were 1.99-, 2.42-, 2.43-, 2.61-, and 2.93-fold
increases in BECLIN-1 protein intensity in 0.1, 1, 10,
Figure 1 mRNA levels of autophagy specific genes in
response to imatinib in K562 cells. 0.1, 1, and 10 nM imatinib
were applied to K562 cells for 72 hours and expression levels
of autophagy specific genes were determined by RT-PCR.
Expression levels of beta-actin were detected as an internal
positive control.
Figure 2 Fold changes in expression levels of autophagy
specific genes Beclin-1 (A) and ATG5 (B) by densitometric
analysis in response to imatinib in K562 cells. Intensities of
RT-PCR products were measured by software and normal-
ized with beta-actin gene expression as a house-keeping
gene.
Figure 3 Fold changes in expression levels of Beclin-1 gene
by real-time PCR in response to imatinib in K562 cells. To
confirm semi-quantitative PCR results, expression levels of
Beclin-1 gene were assessed by real-time PCR. Relative
changes in expression levels of Beclin-1 gene were found by
normalizing with beta-actin gene.
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50, and 100 nM imatinib applied to K562 cells,
respectively, compared to control group (Fig. 4B).
On the other hand, western blot analyses demon-
strated that there were 1.23-, 2.50-, and 3.20-fold
increases in protein levels of ATG5 gene in response
to 1, 10, and 100 nM imatinib in K562 cells,
respectively (Fig. 5).
Discussion
In the current study, we showed that imatinib induces
autophagy in a dose dependent manner in human
K562 CML cells. This induction was shown by the
increases in the expression and protein levels of
autophagy-specific genes which are considered as the
key components of the formation of autophagosomes.
Autophagy is the physiological process in which
cellular components are broken down. This event has
importance for the maintenance of cellular home-
ostasis by partaking roles in organelle turnover,
resistance to stress conditions and defense against
infections. Besides these properties, the literature
indicates that autophagy might contribute to cell
death or cell survival depending on the circum-
stances. It was shown by different groups that
autophagy is a tumor suppressing mechanism, and
defects in the autophagy pathway were associated
with the increased incidence of breast, ovarian and
prostate cancers.23–26 Interestingly, some other
groups demonstrated the significance of autophagy
in cancer cell survival by providing nutrients espe-
cially in poorly vascularized areas and by contribut-
ing to the resistance to cellular stress induced by
radiotherapy.27–29 Under the light of these findings,
autophagy currently gains importance as a target
pathway in cancer therapy.
Imatinib, being the first target specific drug, is a
competitive inhibitor of adenosine triphosphate bind-
ing pocket of BCR/ABL oncogenic protein. Besides
CML, imatinib was shown to be effective for the
suppression of the growth of gastrointestinal stromal
tumors, ovarian cancer cells, neuroendocrine tumor
cells, and melanoma cells.30–33 It was shown that
imatinib can suppress c-KIT in addition to inhibition
of BCR/ABL.30 Inactivation of platelet-derived
growth factor receptor alpha and AKT proteins were
documented to be the main mechanism of action of
imatinib in the suppression of ovarian cancer cells.31
Besides its targets counted so far, imatinib was also
shown to inhibit telomerase activity in both BCR/ABL
expressing and non-expressing cells with the currently
unknown intermediate agents.34 Recently, ceramide
metabolism was implicated to be related to the
imatinib’s mechanism of action.7 In another study,
sphingosine kinase-1 was shown as a downstream
regulator of imatinib-induced apoptosis.35 Our group
recently has shown that imatinib also induces apopto-
sis by inhibiting topoisomerase I and topoisomerase II
enzyme activities in an enzyme specific manner. Since
the efficacy of imatinib is not solely limited to CML,
findings of the scientific studies involving imatinib
might be exploited to other malignancies and diseases.
Autophagy induced by imatinib application might
be either contributing cell death or it might protect
the cell against the stress of this kind of chemother-
apy. Currently ongoing projects aim to expand the
scope of this research to reveal the cellular roles of
autophagic induction by imatinib. Outcomes of this
research may provide novel targets in CML therapy.
If autophagy acts as a protective mechanism for
cancer cell, in this case, drugs blocking autophagy
pathway might be incorporated to the therapy along
with conventional imatinib therapy. This approach
might be useful in treating the imatinib-resistant
Figure 4 Protein levels of Beclin-1 gene in response to
imatinib in K562 cells. (A) Protein levels of Beclin-1 gene in
response to imatinib were determined by western blot.
(B) Fold changes in protein levels were determined by
densitometric analysis.
Figure 5 Protein levels of ATG5 gene in response to
imatinib in K562 cells were determined by western blot and
fold changes in protein levels were determined by densito-
metric analysis.
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CML as well. In contrast, if autophagy is acting as a
cell death mechanism besides the imatinib-dependent
apoptosis, this time, autophagy pathway might be
promoted for more successful CML therapies. By
conducting more research to understand the details of
these scenarios, valuable information will be gained
for developing more effective CML therapy.
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